Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

Phase 1

Terminated

Conditions: Leukaemia

Interventions: Drug: SAR440234

First Posted Date: 2018-07-20

Last Posted Date: 2022-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 7

Registration Number: NCT03594955

Locations: 🇺🇸
Investigational Site Number 8400001, Houston, Texas, United States
🇫🇷
Investigational Site Number 2500003, Villejuif Cedex, France
🇫🇷
Investigational Site Number 2500004, Marseille, France

and more 1 locations

Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis

Phase 3

Completed

Conditions: Pharyngitis

Interventions: Drug: ambroxol BIH1526
Drug: placebo

First Posted Date: 2018-07-11

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 390

Registration Number: NCT03583658

Locations: 🇿🇦
Investigational Site Number 7100005, Johannesburg, South Africa

Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Dupilumab (SAR231893/REGN668)
Drug: Asthma controller therapies (incl. prednisone/prednisolone)
Drug: Asthma reliever therapies

First Posted Date: 2018-06-18

Last Posted Date: 2025-04-24

Lead Sponsor: Sanofi

Target Recruit Count: 365

Registration Number: NCT03560466

Locations: 🇷🇺
Investigational Site Number : 6430005, St Petersburg, Russian Federation
🇷🇺
Investigational Site Number : 6430003, St. Petersburg, Russian Federation
🇿🇦
Investigational Site Number : 7100001, Cape Town, South Africa

and more 78 locations

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: SAR440340
Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Drug: Any short-acting β agonist as prescribed by treating physician as standard of care

First Posted Date: 2018-06-06

Last Posted Date: 2022-11-22

Lead Sponsor: Sanofi

Target Recruit Count: 343

Registration Number: NCT03546907

Locations: 🇦🇷
Investigational Site Number 0320005, Caba, Argentina
🇵🇱
Investigational Site Number 6160002, Poznan, Poland
🇦🇷
Investigational Site Number 0320002, Caba, Argentina

and more 80 locations

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
Drug: INSULIN GLARGINE (HOE901)
Drug: Metformin
Drug: Insulin Glulisine (HMR1964)

First Posted Date: 2018-05-18

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 247

Registration Number: NCT03529123

Locations: 🇮🇳
Investigational Site Number 08, Jaipur, India
🇮🇳
Investigational Site Number 012, Belgaum, India
🇮🇳
Investigational Site Number 017, Coimbatore, India

and more 10 locations

Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders

Phase 1

Completed

Conditions: Sleep Disorder (Healthy Volunteers)

Interventions: Drug: MELATONIN (MELATL07959)

First Posted Date: 2018-05-02

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 40

Registration Number: NCT03514732

Locations: 🇵🇱
Sanofi Administrative Office, Gdańsk, Poland

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolaemia

Interventions: Drug: Alirocumab SAR236553 (REGN727)
Drug: Rosuvastatin
Drug: Atorvastatin
Drug: Simvastatin
Drug: Pravastatin
Drug: Lovastatin
Drug: Fluvastatin
Drug: Ezetimibe
Drug: Cholestyramine
Drug: Nicotinic acid
Drug: Fenofibrate
Drug: Omega-3 fatty acids
Drug: Placebo

First Posted Date: 2018-04-27

Last Posted Date: 2023-05-06

Lead Sponsor: Sanofi

Target Recruit Count: 153

Registration Number: NCT03510884

Locations: 🇪🇸
Investigational Site Number :7240003, Pamplona, Navarra, Spain
🇵🇱
Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
🇲🇽
Investigational Site Number :4840007, Oaxaca, Mexico

and more 40 locations

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Alirocumab SAR236553 (REGN727)
Drug: Atorvastatin
Drug: Simvastatin
Drug: Fluvastatin
Drug: Pravastatin
Drug: Lovastatin
Drug: Rosuvastatin
Drug: Ezetimibe
Drug: Cholestyramine
Drug: Nicotinic acid
Drug: Fenofibrate
Drug: Omega-3 fatty acids

First Posted Date: 2018-04-27

Last Posted Date: 2020-12-29

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT03510715

Locations: 🇩🇰
Investigational Site Number 2080001, Viborg, Denmark
🇪🇸
Investigational Site Number 7240001, A Coruna, Spain
🇸🇮
Investigational Site Number 7050001, Ljubljana, Slovenia

and more 7 locations

Effect of Efpeglenatide on Cardiovascular Outcomes

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Efpeglenatide (SAR439977)

First Posted Date: 2018-04-12

Last Posted Date: 2021-10-15

Lead Sponsor: Sanofi

Target Recruit Count: 4076

Registration Number: NCT03496298

Locations: 🇺🇸
Investigational Site Number 8400096, Philadelphia, Pennsylvania, United States
🇺🇸
Investigational Site Number 8400021, Pittsburgh, Pennsylvania, United States
🇮🇳
Investigational Site Number 3560005, Pune, India

and more 350 locations

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Phase 3

Active, not recruiting

Conditions: Gaucher's Disease Type I
Gaucher's Disease Type III

Interventions: Drug: Eliglustat GZ385660
Drug: Imiglucerase GZ437843

First Posted Date: 2018-04-02

Last Posted Date: 2024-02-20

Lead Sponsor: Sanofi

Target Recruit Count: 57

Registration Number: NCT03485677

Locations: 🇨🇦
Investigational Site Number : 1240002, Calgary, Alberta, Canada
🇦🇷
Investigational Site Number : 0320001, Capital Federal, Buenos Aires, Argentina
🇨🇦
Investigational Site Number : 1240003, Vancouver, British Columbia, Canada

and more 18 locations

Home Terms & Conditions Privacy Policy